Defeating Malaria Together

ATLANTA, GEORGIA, USA, 11–15 NOVEMBER, 2012

MMV @ ASTMH American Society of Tropical Medicine and Hygiene (ASTMH) 61st Annual Meeting

MMV @ ASTMH ATLANTA, GEORGIA, USA, 11–15 NOVEMBER, 2012

Symposium: session 15

Marriott, Marquis B, Monday, 12 Nov, 10:15 am – 12:00 pm

Drug discovery strategy for malaria eradication Symposium organizer: Brice Campo, MMV, SwitzerlandCo-chairperson: Philip Rosenthal, University of California, USA

Speakers 10:15 am New tools to discover liver-stage drugs for human malaria Dennis E. Kyle, University of South Florida, USA10:40 am Culturing of Plasmodium vivax to develop sporozoites Kasturi Haldar, University of Notre Dame, USA11:05 am Developing the next generation of high content / high throughput assays to identify novel antimalarials with transmission-blocking activity Vicky M. Avery, Griffith University, Australia11:30 am Assays to screen for transmission-blocking drugs Michael Delves, Imperial College London, UK

Scientific session 30

Marriott, Marquis B, Monday, 12 Nov, 1:45 pm – 3:30 pm

Malaria drug development: primaquine and new developments Co-Chairs Mark Baker, MMV, Switzerland Prabhati Ray, Walter Reed Army Institute of Research, USA

Speakers 1:45 pm 431. ELQ-300 for treatment and prevention of malaria, Michael K. Riscoe, Oregon Health & Science University, USA 2:00 pm 432. Potential efficacy of Citicoline as adjunct therapy for cerebral malaria Ronan Jambou, Institut Pasteur de Madagascar, Madagascar2:15 pm 433. Pathways to hemolytic toxicity of primaquine: Evaluation of potential hemotoxic metabolites of primaquine and aminophenol analogs in vitro on normal and glucose 6-phosphate dehydrogenase deficient human erythrocytes Babu L. Tekwani, University of Mississippi, USA2:30 pm 434. An in vivo glucose-6-phosphate dehydrogenase (G6PD)-deficient mouse model to predict hemolytic toxicity of candidate 8-aminoquinoline (8-AQ) antimalarial drugs Prabhati Ray, Walter Reed Army Institute of Research, USA2:45 pm 435. Phase I study to investigate the haemolytic potential of tafenoquine in healthy subjects with G6PD deficiency (TAF110027) Ronnatrai Rueangweerayut, Mae Sot General Hospital, Thailand3:00 pm 436. Using human blood stage P. falciparum infection to define the activity of licensed and experimental antimalarial drugs James S. McCarthy, University of Queensland, Australia3:15 pm 437. A population pharmacokinetic analysis of OZ439 disposition in patients Mark B. Baker, MMV, Switzerland

PROGRAMME

MMV @ ASTMH ATLANTA, GEORGIA, USA, 11–15 NOVEMBER, 2012

Symposium: session 57

Marriott, Marquis D, Tuesday, 13 Nov 2012, 8:00 am – 9:45 am (Breakfast will be available)

Evaluating the modelling effects of implementing multiple first-line (MFL) artemisinin combination therapy (ACT) treatments versus real-life dataSymposium organizer: Ric Price, Menzies School of Health Research, AustraliaCo-chairperson: Pierre Hugo, MMV, Switzerland

Speakers 8:00 am Modelling the impact of implementing different ACTs as first-line therapy Azra Ghani, Imperial College London, UK8:20 am Modelling the benefits of implementing MFL treatments in Ghana within high and low transmission settings: INDEPTH Effectiveness and Safety Study (INESS) sites for antimalarials Fred Binka, University of Ghana, Ghana8:40 am Modelling the benefits of implementing MFL treatments in Tanzania within high transmission and low transmission settings. How does the modelling data complement INESS results data? Don de Savigny, Swiss TPH, Switzerland9:05 am Modelling vs. real-life setting’s longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria Grant Dorsey, University of California, USA

www.mmv.org

Medicines for Malaria Venture’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease. www.mmv.org | info@mmv.org

MMV @ ASTMH ATLANTA, GEORGIA, USA, 11–15 NOVEMBER, 2012

Symposium: session 144

Marriott, Marquis A, Wednesday, 14 Nov, 4:00 pm – 5:45 pm

Partnerships against malaria Symposium organizer: Wilfred Fon Mbacham, The Multilateral Initiative on Malaria, CameroonCo-chairperson: Abdoulaye A. Djimde, University of Bamako, Mali

Speakers 10:15 am The Worldwide Antimalarial Resistance Network (WWARN) Philippe Guérin, WWARN, UK4:20 pm The production of semi-synthetic artermisinins Nina Grove, One World Health, USA4:40 pm Training of public health professionals and scientists, the Ifakara (Tanzania) and Madagascar experience Milijoan Randrianariveljosia, Institut Pasteur, Madagascar5:00 pm New antimalarials: addressing the risk of resistance development and planning for elimination Stephan Duparc, MMV, Switzerland

Poster presentations

Hilton, Galleria Hall, Monday, 12 Nov 2012, 12:00 pm – 1:45 pmSession 24: Poster Session A Presentations and Light Lunch

150. A randomized, placebo-controlled study to evaluate the effect of tafenoquine on the electrocardiogram (ECG), with focus on cardiac repolarization (QTc duration) in healthy subjects

Justin A. Green, Apurva K. Patel, Azra Hussaini, Emma J. Harrell, Mirna J. McDonald, Ann K. Miller, Stephan Duparc

Hilton, Galleria Hall, Wednesday, 14 Nov 2012, 12:00 pm – 1:45 pmSession 128: Poster Session C Presentations and Light Lunch

1292. The drug-drug interaction potential of anti-malarial agents

Mark Baker